EUVIMEDSkopri EUVIMED
Crossref

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study

Sean McKeague, Pietro R Di Ciaccio, Steven Tran, Adrian Minson, David Richie, Glen Kennedy, Sam Milliken, Duncan Purtill, David Gottlieb, Travis Perera, David T Yeung, Stephen R Larsen and 8 more

Internal Medicine Journal · 2026

DOI: 10.1111/imj.70541 ↗

At a glance

Journal article in Internal Medicine Journal, 2026. Written by Sean McKeague and 19 co-authors. Institution: Department of Haematology, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia. Major MEDLINE topics: Lymphoma, Mantle-Cell, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation. 33 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Allogeneic stem cell transplantation (AlloSCT) has established curative potential in mantle cell lymphoma (MCL). As therapies for MCL evolve, outcomes with AlloSCT require reassessment.

Aim

This study aimed to report the outcomes of AlloSCT for MCL across Australia and New Zealand.

Methods

Data were collected through the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) for all patients undergoing AlloSCT for MCL between January 2009 and December 2019.

Results

Forty‐six patients underwent AlloSCT for MCL between 2009 and 2014 and 40 between 2015 and 2019. The median patient age was 56 years (range 32–72), nine of 15 patients tested (60%) had TP53 mutation, and 14% of patients underwent myeloablative conditioning (MAC). A higher proportion of patients in the 2015–2019 period were BTKi‐exposed (68% vs. 0%, P = 0.00). Non‐relapse mortality (NRM) at 1 year and 5 years was 23% (95% confidence interval (95% CI) 14–32) and 31% (95% CI 21–42) respectively. The 100‐day cumulative incidence of grade II to IV acute graft‐versus‐host disease (GVHD) was 21% (95% CI 13–30), and the 3‐year cumulative incidence of chronic GVHD was 31% (95% CI 22–41). At 5 years, overall survival (OS) was 48% (95% CI 36–59) and progression free survival (PFS) was 38% (95% CI 27–50). The use of MAC was independently associated with inferior PFS (hazard ratio [HR] 2.33, 95% CI 1.05–5.17, P = 0.038) and OS (HR 3.11, 95% CI 1.39–7.00, P = 0.006). There was no difference in outcomes for patients transplanted between 2009 and 2014 versus 2015 and 2019.

Conclusion

AlloSCT can achieve durable remissions for MCL in the modern era, and the use of MAC is associated with inferior outcomes.

Subjects

MeSH terms (MEDLINE)

Lymphoma, Mantle-CellTransplantation ConditioningHematopoietic Stem Cell TransplantationHumansFemaleNew ZealandAustraliaAdultMaleRegistriesMiddle AgedAgedTransplantation, HomologousRemission InductionTreatment OutcomeGraft vs Host Disease

Author keywords

AllograftMantle cell lymphomaTransplantconditioning

Authors and institutions

  • Department of Haematology, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.
  • Department of Haematology, The Canberra Hospital, Australian National University, Canberra, Australian Capital Territory, Australia.
  • Department of Haematology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
  • Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Department of Haematology, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.

Cite

APA

McKeague, S., Di Ciaccio, P. R., Tran, S., Minson, A., Richie, D., Kennedy, G., Milliken, S., Purtill, D., Gottlieb, D., Perera, T., Yeung, D. T., Larsen, S. R., Doocey, R., Greenwood, M., Durrant, S., Watson, A. M., Butler, A., Khot, A., Curley, C., & Hamad, N. (2026). Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study. Internal Medicine Journal. https://doi.org/10.1111/imj.70541

Vancouver

McKeague S, Di Ciaccio PR, Tran S, Minson A, Richie D, Kennedy G, et al. Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study. Internal Medicine Journal. 2026. doi:10.1111/imj.70541

BibTeX
@article{McKeague2026,
  author = {McKeague, Sean and Di Ciaccio, Pietro R and Tran, Steven and Minson, Adrian and Richie, David and Kennedy, Glen and Milliken, Sam and Purtill, Duncan and Gottlieb, David and Perera, Travis and Yeung, David T and Larsen, Stephen R and Doocey, Richard and Greenwood, Matthew and Durrant, Simon and Watson, Anne-Marie and Butler, Andrew and Khot, Amit and Curley, Cameron and Hamad, Nada},
  title = {Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70541}
}
Start for free →